Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.

NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators

TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.

METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help

NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product

COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors

INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
AXSM Shariah Compliance
Screening Methodology: AAOIFI
HALAL
Last Updated: May 11, 2026
Report Source: 2026 1st Quarter Report
Axsome Therapeutics Inc. Stock Analysis AXSM
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. The company is headquartered in New York City, New York and currently employs 925 full-time employees. The company went IPO on 2015-11-19. The firm focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. The company is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Read More Axsome Therapeutics Inc (AXSM) Chart
Key Statistics of Axsome Therapeutics Inc (AXSM)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$247.85Volume
1.31MP/E Ratio (TTM)
-52 Week Range
Market Cap
12.02BAvg. Volume
714.49KDividend Yield
-Financial Metrics & Statements of Axsome Therapeutics Inc (AXSM)
FAQ's for Axsome Therapeutics Inc (AXSM)
- According to Musaffa’s Shariah screening methodology, Axsome Therapeutics Inc (AXSM) is currently classified as HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Axsome Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Axsome Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Axsome Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Axsome Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Axsome Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.